Literature DB >> 30969955

Treatment of relapsed/refractory acute lymphoblastic leukemia.

Shilpa Paul1, Caitlin R Rausch1, Patrice E Nasnas1, Hagop Kantarjian1, Elias J Jabbour1.   

Abstract

Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity. Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30969955

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


  9 in total

1.  microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis.

Authors:  Xiaojun Sun; Guotao Guan; Yunpeng Dai; Ping Zhao; Liying Liu; Qi Wang; Xiuli Li
Journal:  Lab Invest       Date:  2021-11-13       Impact factor: 5.662

2.  Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Yi-Fen Shi; Na Wang; Zi-Yang Huang; Rong-Rong Chen; Yi-Sha Huang; Yi-Yi Zhu; Chong-Yun Xing; Bin Liang; Kang Yu; Jian-Hua Feng
Journal:  Cancer Manag Res       Date:  2020-08-10       Impact factor: 3.989

3.  Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.

Authors:  Hiroaki Goto; Yuki Yoshino; Mieko Ito; Junichi Nagai; Tadashi Kumamoto; Takesi Inukai; Yukari Sakurai; Naoyuki Miyagawa; Dai Keino; Tomoko Yokosuka; Fuminori Iwasaki; Satoshi Hamanoue; Masae Shiomi; Shoko Goto
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-06       Impact factor: 3.333

4.  Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.

Authors:  Francesca Bonifazi; Chiara Pavoni; Jacopo Peccatori; Fabio Giglio; Mario Arpinati; Alessandro Busca; Paolo Bernasconi; Anna Grassi; Anna Paola Iori; Francesca Patriarca; Lucia Brunello; Carmen Di Grazia; Angelo Michele Carella; Daniela Cilloni; Alessandra Picardi; Anna Proia; Stella Santarone; Roberto Sorasio; Paola Carluccio; Patrizia Chiusolo; Alessandra Cupri; Mario Luppi; Chiara Nozzoli; Donatella Baronciani; Marco Casini; Giovanni Grillo; Maurizio Musso; Francesco Onida; Giulia Palazzo; Matteo Parma; Stefania Tringali; Adriana Vacca; Daniele Vallisa; Nicoletta Sacchi; Elena Oldani; Arianna Masciulli; Angela Gheorghiu; Corrado Girmenia; Massimo Martino; Benedetto Bruno; Alessandro Rambaldi; Fabio Ciceri
Journal:  Bone Marrow Transplant       Date:  2022-04-12       Impact factor: 5.174

5.  CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study.

Authors:  Jie-Jing Qian; Xiaoxia Hu; Ying Wang; Yi Zhang; Juan Du; Min Yang; Hongyan Tong; Wen-Bin Qian; Juying Wei; Wenjun Yu; Yin-Jun Lou; Liping Mao; Hai Tao Meng; Liang-Shun You; Libing Wang; Xia Li; Xin Huang; Li-Hong Cao; Jian-Zhi Zhao; Xiao Yan Yan; Yu-Bao Chen; Yu Chen; Su-Jiang Zhang; Jie Jin; Jiong Hu; Hong-Hu Zhu
Journal:  Cancer Med       Date:  2020-06-03       Impact factor: 4.452

6.  Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy.

Authors:  Zhongbo Hu; Kristen A VanHeyst; Jignesh Dalal; Lisa Hackney
Journal:  Clin Case Rep       Date:  2021-02-12

Review 7.  Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia.

Authors:  Silvia Jiménez-Morales; Ivan Sammir Aranda-Uribe; Carlos Jhovani Pérez-Amado; Julian Ramírez-Bello; Alfredo Hidalgo-Miranda
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

Review 8.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 9.  The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001.

Authors:  Esteve Trias; Manel Juan; Alvaro Urbano-Ispizua; Gonzalo Calvo
Journal:  Bone Marrow Transplant       Date:  2022-01-19       Impact factor: 5.483
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.